GenScript ProBio Opens China’s Largest Commercial GMP Plasmid Manufacturing Facility
8.12.2021 12:00:00 EET | Business Wire | Press release
GenScript ProBio announced today the opening of China's largest commercial GMP plasmid manufacturing facility during a ceremony at the site in Zhenjiang, Jiangsu Province. The 6,400-square-meter manufacturing plant enables GenScript ProBio to offer global customers a one-stop service for plasmids - from preclinical study (IIT), to investigational new drug (IND) filing, to clinical trial and commercial manufacturing - to accelerate the innovation and development of high-quality cell and gene therapy mRNA drugs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005385/en/
GenScript ProBio’s largest commercial GMP plasmid manufacturing facility in China opens in Zhenjiang, Jiangsu Province. (Photo: Business Wire)
As GenScript ProBio's second GMP plasmid manufacturing facility, the plant more than doubles the company's production capacity and strengthens its position as a leading CDMO. It enables the company to offer services including off-the-shelf LentiHelpTM plasmids, Pro grade plasmids for preclinical development, plasmids CMC study for IND filing, clinical GMP plasmids for early clinical trials, and cGMP plasmids for late-phase and commercialization.
The facility also expands GenScript ProBio's operations, which already included the largest commercial GMP plasmid manufacturing facility in China. GenScript ProBio is the first CDMO enterprise in China to have separate production facilities for plasmids and viral vectors. GenScript ProBio is the only GMP manufacturing platform in China that provides in vitro transcription (IVT) template linearized plasmids for mRNA vaccines.
In 2020, GenScript ProBio helped Suzhou Abogen secure the first clinical approval for an mRNA vaccine in China, and in October 2021, it reached an agreement with Abogen and Walvax for commercial manufacturing of the vaccine. Besides helping many mRNA vaccine enterprises in China obtain clinical approvals by NMPA, GenScript ProBio also supported companies in South Korea and the United States as they sought clinical approvals for mRNA vaccines in South Korea and Japan.
“GenScript ProBio adheres to the mission of‘Innovation through Collaboration.’Our extensive experience and high-quality plasmid viral vector manufacturing services have helped customers worldwide advance their clinical trials and commercial development programs," said Dr. Brian Min, CEO of GenScript ProBio, during a speech at the opening ceremony. "Our GMP plasmid manufacturing for mRNA vaccine development has also helped our customers in the fight against the COVID-19 pandemic."
Since its founding GenScript ProBio has supported the development of cell and gene therapies. In 2018, GenScript ProBio helped its subsidiary Legend Biotech secure the first CAR-T clinical approval in China. In 2019 and 2020, GenScript ProBio, as a service provider of Xiangxue, helped it secure the first TCR-T project approval from the NMPA, as well as approval from the FDA. The filing in China took only 54 working days from the submission of the IND application to the receipt of the Notification of Drug Clinical Trials, setting a record for the fastest new drug approval in 2019 in China.
About GenScript ProBio
GenScript ProBio is the biologics CDMO segment of GenScript Biotech, proactively providing end-to-end service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in antibody drug and gene and cell therapy to accelerate drug development for customers. https://www.genscriptprobio.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005385/en/
Contact information
Berkan Unal, Director Business Development
E-mail: berkan.unal@genscript.com
Phone: +49 176 233 22 401
Shanlin Yang, Media Relations Manager
E-mail: shanlin.yang@genscript.com
Phone: +86 150 7138 1167
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Private Markets Firms Face SPV Execution Pressure as LP Demands Rise3.6.2026 15:30:00 EEST | Press release
As private markets firms navigate a more challenging fundraising and exit environment, limited partners (LPs) are demanding greater transparency, stronger governance rights, and more flexible SPV arrangements from fund managers. In fact, 86% of private markets professionals report increased LP requests for tailored SPV structures over the past 12 months, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC¹ surveyed 410 senior private markets practitioners across private equity, private credit, real estate, and infrastructure to examine how investor demands are reshaping SPV structures, operating models, and execution requirements. The findings are detailed in CSC’s new report SPV Global Outlook 2026: How LP demands and operational complexity are reshaping the SPV model. The research reveals that enhanced transparency and reporting is now the leading LP demand, cited by 76% of respondents. Stronger governance and approval
New Evidence Offers Hope for Ketogenic Therapy in Treatment of Anorexia Nervosa3.6.2026 15:00:00 EEST | Press release
A pilot study published today in Communications Medicine demonstrates the potential of a new approach to treating anorexia nervosa — a disorder for which effective treatments have been significantly limited. The research from UC San Diego School of Medicine reports that a ketogenic nutritional intervention — a high-fat, low-carbohydrate, moderate-protein diet — was feasible and safe for patients with weight-normalized and mildly underweight anorexia nervosa. The ketogenic intervention was well-tolerated by participants, with high adherence rates and no significant weight loss observed throughout the program. Furthermore, significant improvements were observed in eating disorder symptoms, with nearly 3 in 4 of study completers in the recovered range at study end, no longer meeting criteria for an anorexia nervosa diagnosis, and all completers experiencing an improvement in depression scores. This press release features multimedia. View the full release here: https://www.businesswire.com
NetApp and Cisco Collaboration Strengthens Defense-in-Depth for Enterprise Cyber Resilience3.6.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Cisco (NASDAQ: CSCO), today announced an expansion of their collaboration to help customers strengthen defense-in-depth strategies for customers. Combining Intelligent Data Infrastructure with advanced analytics and observability capabilities, NetApp and Splunk have delivered deep, real-time visibility into storage and infrastructure health. Together, they are helping customers turn operational data into actionable insights that improve reliability, security, and business outcomes. By expanding their collaboration with the new NetApp Splunk Security Orchestration, Automation, and Response (SOAR) playbook, NetApp and Splunk are helping joint customers contain ransomware attacks and limit data loss at the storage layer, enhancing the containment of the blast radius of cyberattacks while increasing the speed and reducing the cost of recovery. “With AI accelerating both the speed and sophistication of cyberattacks, th
NetApp and Cisco Accelerate and Secure AI Innovation3.6.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Cisco (NASDAQ: CSCO) today announced that they have collaborated to offer new validated solutions for secure, scalable, and simplified AI. Expanding the proven success of FlexPod, the new solutions provide a simple, reliable path for enterprises to address the specific challenges AI workloads place on compute, network, and storage infrastructure. “As IT teams are tasked with delivering reliable, consistent performance across environments, AI workloads are placing increasing demands on their data infrastructure,” said Dallas Olson, Chief Commercial Officer at NetApp. “NetApp and Cisco’s longstanding partnership on FlexPod has already proven effective, saving customers up to 20 percent of their time in infrastructure management and maintenance. Now, we are applying our combined expertise to modern challenges to accelerate AI adoption while reducing risk with built-in security.” NetApp and Cisco are expanding FlexPod
NIQ Named 2026 Retail & Consumer Goods Snowflake Product Partner of the Year3.6.2026 14:00:00 EEST | Press release
NielsenIQ (NYSE:NIQ) today announced that it has been named the 2026 Retail & Consumer Goods Snowflake Product Partner of the Year award recipient by Snowflake, the AI Data Cloud company. NIQ was recognized for its achievements at Snowflake’s annual user conference, Snowflake Summit 26, for delivering scalable, cloud-native solutions on Snowflake that enable retailers, brands, and media partners to securely enrich data, measure performance, and unlock more precise, actionable commerce intelligence. Through Snowflake’s AI Data Cloud, NIQ helps joint customers collaborate across organizations, activate high-value data assets, and power advanced measurement while maintaining strong governance and data privacy controls. By embedding NIQ’s AI-driven data, models, and harmonization capabilities within Snowflake, customers can unify fragmented datasets into a trusted, scalable foundation for AI. This makes it easier to operationalize AI-powered decision-making and move faster from insight to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom